Rapcabtagene autoleucel + Glucocorticoids
Phase 2RecruitingInterest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA Associated Vasculitis (AAV)
Conditions
ANCA Associated Vasculitis (AAV)
Trial Timeline
Mar 13, 2025 → May 24, 2030
NCT ID
NCT06868290About Rapcabtagene autoleucel + Glucocorticoids
Rapcabtagene autoleucel + Glucocorticoids is a phase 2 stage product being developed by Novartis for ANCA Associated Vasculitis (AAV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06868290. Target conditions include ANCA Associated Vasculitis (AAV).
What happened to similar drugs?
1 of 3 similar drugs in ANCA Associated Vasculitis (AAV) were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06868290 | Phase 2 | Recruiting |
Competing Products
10 competing products in ANCA Associated Vasculitis (AAV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan + Placebo + Rituximab | Novartis | Phase 2 | 39 |
| CellCept (mycophenolate mofetil) | Roche | Phase 1 | 29 |
| rituximab + Placebo | Roche | Phase 3 | 40 |
| Avacopan, prednisolone and rituximab + Prednisolone and rituximab | Kissei Pharmaceutical | Approved | 50 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Amgen | Phase 2 | 35 |
| Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine | Amgen | Phase 3 | 40 |
| Abatacept (Orencia) | Bristol Myers Squibb | Phase 2 | 27 |
| Sparsentan | Travere Therapeutics | Phase 2 | 33 |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy | Kyverna Therapeutics | Phase 1/2 | 33 |
| FT819 + Fludarabine + Cyclophosphamide + Bendamustine | Fate Therapeutics | Phase 1 | 26 |